Abstract
Using the reverse protein array platform in combination with planar waveguide technology, which allows detection of proteins in spotted cell lysates with high sensitivity in a 96-well microtiter-plate format for growing, treating, and lysing cells was shown to be suitable for this approach and indicates the usefulness of the technology as a screening tool for characterization of large numbers of kinase inhibitors. In this study, we have used reverse protein arrays to profile kinase inhibitors in various cellular pathways in order to unravel their MoA. Multiplexing and simultaneous analysis of several phospho-proteins within the same lysate allows (1) the estimation of inhibitor concentrations needed to shut down an entire pathway, (2) the estimation of inhibitor selectivity, and (3) the comparison of inhibitors of different kinases within one assay. For example, parallel analysis of p-InsR, p-PKB, p-GSK-3, p-MEK, p-ERK, and p-S6rp in insulin treated A14 cells allows profiling for inhibitors of the InsR, PI3K, PKB, mTor, RAF, and MEK. Selective kinase inhibitors revealed different specific inhibitory pattern of the analyzed phospho-read outs. Altogether, multiplexed analysis of reverse (phase) protein arrays is a powerful tool to characterize kinase inhibitors in a semi-automated low to medium throughput assay format.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fishman, M.C. & Porter, J.A. Pharmaceuticals: a new grammar for drug discovery. Nature 437, 491–3 (2005).
Inoki, K., Corradetti, M.N. & Guan, K.L. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37, 19–24 (2005).
Butcher, E.C. Can cell systems biology rescue drug discovery? Nat Rev Drug Discov 4, 461–7 (2005).
Apic, G., Ignjatovic, T., Boyer, S. & Russell, R.B. Illuminating drug discovery with biological pathways. FEBS Lett 579, 1872–7 (2005).
Butcher, E.C., Berg, E.L. & Kunkel, E.J. Systems biology in drug discovery. Nat Biotechnol 22, 1253–9 (2004).
Sevecka, M. & MacBeath, G. State-based discovery: a multidimensional screen for small-molecule modulators of EGF signaling. Nat Methods 3, 825–31 (2006).
Cho, C.R., Labow, M., Reinhardt, M., van Oostrum, J. & Peitsch, M.C. The application of systems biology to drug discovery. Curr Opin Chem Biol 10, 294–302 (2006).
Mendes, K.N. et al. Analysis of signaling pathways in 90 cancer cell lines by protein lysate array. J Proteome Res 6, 2753–67 (2007).
Sheehan, K.M. et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 4, 346–55 (2005).
Pawlak, M. et al. Zeptosens’ protein microarrays: a novel high performance microarray platform for low abundance protein analysis. Proteomics 2, 383–93 (2002).
Wang, Z.G. et al. TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells. Oncol Rep 20, 1473–7 (2008).
Maira, S.M. et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7, 1851–63 (2008).
Schuler, W. et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64, 36–42 (1997).
Barrett, S.D. et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett 18, 6501–4 (2008).
Huynh, H., Soo, K.C., Chow, P.K. & Tran, E. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther 6, 138–46 (2007).
Changelian, P.S. et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302, 875–8 (2003).
Traxler, P. et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 64, 4931–41 (2004).
Burgering, B.M. et al. Insulin stimulation of gene expression mediated by p21ras activation. Embo J 10, 1103–9 (1991).
Zhang, J.H., Chung, T.D. & Oldenburg, K.R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4, 67–73 (1999).
De Meyts, P. & Whittaker, J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 1, 769–83 (2002).
Kanzaki, M. & Pessin, J.E. Signal integration and the specificity of insulin action. Cell Biochem Biophys 35, 191–209 (2001).
Kusari, A.B., Byon, J.C. & Kusari, J. Substitution of two insulin receptor carboxy-terminal tyrosines with phenylalanine impairs the expression of MAP kinase phosphatase-1 (MKP-1) mRNA. Mol Cell Biochem 211, 27–37 (2000).
Sarbassov, D.D., Guertin, D.A., Ali, S.M. & Sabatini, D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098–101 (2005).
Srivastava, A.K. & Pandey, S.K. Potential mechanism(s) involved in the regulation of glycogen synthesis by insulin. Mol Cell Biochem 182, 135–41 (1998).
Alessi, D.R. et al. Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1. Embo J 13, 1610–9 (1994).
Murphy, L.O. & Blenis, J. MAPK signal specificity: the right place at the right time. Trends Biochem Sci 31, 268–75 (2006).
Peterson, R.T. & Schreiber, S.L. Translation control: connecting mitogens and the ribosome. Curr Biol 8, R248-50 (1998).
White, M.F., Maron, R. & Kahn, C.R. Insulin rapidly stimulates tyrosine phosphorylation of a Mr-185,000 protein in intact cells. Nature 318, 183–6 (1985).
Foxwell, B.M., Barrett, K. & Feldmann, M. Cytokine receptors: structure and signal transduction. Clin Exp Immunol 90, 161–9 (1992).
Yamaoka, K. et al. The Janus kinases (Jaks). Genome Biol 5, 253 (2004).
Kisseleva, T., Bhattacharya, S., Braunstein, J. & Schindler, C.W. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285, 1–24 (2002).
Murray, P.J. The JAK-STAT signaling pathway: input and output integration. J Immunol 178, 2623–9 (2007).
O’Shea, J.J., Gadina, M. & Schreiber, R.D. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109 Suppl, S121-31 (2002).
Stark, G.R., Kerr, I.M., Williams, B.R., Silverman, R.H. & Schreiber, R.D. How cells respond to interferons. Annu Rev Biochem 67, 227–64 (1998).
Mogensen, K.E., Lewerenz, M., Reboul, J., Lutfalla, G. & Uze, G. The type I interferon receptor: structure, function, and evolution of a family business. J Interferon Cytokine Res 19, 1069–98 (1999).
Yeh, T.C. & Pellegrini, S. The Janus kinase family of protein tyrosine kinases and their role in signaling. Cell Mol Life Sci 55, 1523–34 (1999).
Durbin, J.E., Hackenmiller, R., Simon, M.C. & Levy, D.E. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84, 443–50 (1996).
Schindler, C., Fu, X.Y., Improta, T., Aebersold, R. & Darnell, J.E., Jr. Proteins of transcription factor ISGF-3: one gene encodes the 91-and 84-kDa ISGF-3 proteins that are activated by interferon alpha. Proc Natl Acad Sci USA 89, 7836–9 (1992).
Takeda, K. et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA 94, 3801–4 (1997).
Vogel, S. et al. MEK hyperphosphorylation coincides with cell cycle shut down of cultured smooth muscle cells. J Cell Physiol 206, 25–34 (2006).
Okuzumi, T. et al. Inhibitor hijacking of Akt activation. Nat Chem Biol 5, 484–93 (2009).
Cameron, A.J., Escribano, C., Saurin, A.T., Kostelecky, B. & Parker, P.J. PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity. Nat Struct Mol Biol 16, 624–30 (2009).
de Wet, J.R., Wood, K.V., DeLuca, M., Helinski, D.R. & Subramani, S. Firefly luciferase gene: structure and expression in mammalian cells. Mol Cell Biol 7, 725–37 (1987).
Fan, F. & Wood, K.V. Bioluminescent assays for high-throughput screening. Assay Drug Dev Technol 5, 127–36 (2007).
Zlokarnik, G. et al. Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter. Science 279, 84–8 (1998).
Chin, J. et al. Miniaturization of cell-based beta-lactamase-dependent FRET assays to ultra-high throughput formats to identify agonists of human liver X receptors. Assay Drug Dev Technol 1, 777–87 (2003).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Martiny-Baron, G., Haasen, D., D’Dorazio, D., Voshol, J., Fabbro, D. (2011). Characterization of Kinase Inhibitors Using Reverse Phase Protein Arrays. In: Korf, U. (eds) Protein Microarrays. Methods in Molecular Biology, vol 785. Humana Press. https://doi.org/10.1007/978-1-61779-286-1_7
Download citation
DOI: https://doi.org/10.1007/978-1-61779-286-1_7
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-285-4
Online ISBN: 978-1-61779-286-1
eBook Packages: Springer Protocols